While it has been shown that (a) glioblastoma cells containing an ND5 mutation or an ND6 mutation are more resistant to rotenone (a Complex I inhibitor) and to adriamycin (a chemotherapeutic drug activated by Complex I redox signaling,) [34], respectively, and (b) yeast complex III engineered to contain an analogue of F18L is more sensitive to clomipramine [31], this is the first account of human cells containing F18L showing enhanced clomipramine sensitivity. This evidence concerns the gene MT-ND5 and glioblastoma.